The gamma interferon gene knockout mouse: a highly sensitive model for evaluation of therapeutic agents against Cryptosporidium parvum.
Cryptosporidiosis is a serious disease in malnourished children and in people with malignancies or AIDS. Current rodent models for evaluating drug therapy against cryptosporidiosis have many limitations, including the need for a high inoculum, the absence of symptoms resembling those seen in humans, and the need to maintain exogenous immunosuppression. We have developed a gamma interferon knockout (GKO) mouse model with which to evaluate therapies against C. parvum and have used paromomycin for evaluation of this model. The GKO model offers considerable improvements over other systems, since it requires no additional immunosuppression and adult mice can be infected with as few as 10 oocysts (compared with 10(7) for SCID mice). Infected mice develop profound gastrointestinal dysfunction due to extensive infection and severe mucosal damage involving the entire small intestine. Clinical symptoms, which include depression, anorexia, weight loss, and wasting, result in death within 2 to 4 weeks. The time of death depends on the oocyst challenge dose. Paromomycin modulated parasitological and clinical parameters in highly predictable and significant ways, including prevention of death. In addition, examination of the extensively infected gut provided an important insight into the dynamics between a specific drug treatment, its impact on the extent and the site of parasite distribution, and clinical outcome. These uniform symptoms of weight loss, wasting, and death are powerful new parameters which bring this model closer to the actual disease seen in humans and other susceptible mammalian species.
Division of Infectious Disease, Tufts University School of Veterinary Medicine, North Grafton, Massachusetts 01536, USA.
J K
JK
Griffiths
C
C
Theodos
M
M
Paris
S
S
Tzipori
D000563:Amebicides / Q000627:therapeutic use*; D000818:Animals; D002648:Child; D003457:Cryptosporidiosis / Q000188:drug therapy* / Q000276:immunology*; D016785:Cryptosporidium parvum / Q000302:isolation & purification; D006801:Humans; D007371:Interferon-gamma / Q000172:deficiency* / Q000235:genetics / Q000502:physiology; D007413:Intestinal Mucosa / Q000469:parasitology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D010303:Paromomycin / Q000627:therapeutic use*; D013997:Time Factors
D000563:Amebicides; D010303:Paromomycin; D007371:Interferon-gamma